Listed by the USPTO as PECKHAM, RICHARD GRANT
Tech Center 1700 • Art Units: 1600 1619 1626 1627 1653 1743
This examiner grants 68% of resolved cases
Peckham, Richard Grant is assigned to Tech Center 1700 and Art Unit 1600, with 138 resolved cases. The allowance rate is 68.1%, the interview lift is 36.1%, and the median time to allowance is 1195 days. The allowance rate is higher than the interview measure, while the positive lift indicates that interviews may be useful in a prosecution process with extended timing.
The listed companies are Praetego Inc., BASF SE, and Levon Michael Khachigian. The leading firms are WILSON SONSINI GOODRICH & ROSATI, Knobbe, Martens, Olson & Bear, LLP, and QUARLES & BRADY LLP. The resolved-case volume supports directional planning, but applicants should continue to rely on claim-specific analysis.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17265139 | HISTONE DEMETHYLASE 5 INHIBITORS AND USES THEREOF | Final Rejection | DANA-FARBER CANCER INSTITUTE, INC. |
| 18854174 | DIHYDROQUINAZOLINONES EXHIBITING IMPROVED PROTECTIVE ACTIVITY AGAINST INTRACELLULARLY ACTING TOXINS AND INTRACELLULAR VIRUSES AND BACTERIA | Non-Final OA | COMMISSARIAT À L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES |
| 18290328 | NEW SUBSTITUTED PYRIDINES AS FUNGICIDES | Final Rejection | BASF SE |
| 19017773 | BORON CARRYING AGENT, PREPARATION METHOD AND PHARMACEUTICAL FORMULATION THEREOF | Non-Final OA | Peking University |
| 18546143 | Small Molecule Inhibitors of PBRM1-BD2 | Final Rejection | The Medical College of Wisconsin, Inc. |
| 18557775 | METHOD FOR PREPARING INTERMEDIATE FOR SYNTHESIS OF XANTHINE OXIDASE INHIBITOR | Non-Final OA | LG CHEM, LTD. |
| 18850038 | MICROWAVE ABSORBER | Non-Final OA | OSAKA UNIVERSITY |
| 18629894 | LASOFOXIFENE TREATMENT OF BREAST CANCER | Non-Final OA | Duke University |
| 17925185 | METABOLIC INHIBITORS WITH EFFICACY FOR INHIBITING SULFIDE PRODUCTION IN HARSH ENVIRONMENTS | Non-Final OA | LANXESS Corporation |
| 18726889 | COMPOSITIONS AND METHODS FOR TREATING MACULAR EDEMA ASSOCIATED WITH UVEITIS | Non-Final OA | Clearside Biomedical, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy68.1% of resolved applications examined by Richard Grant Peckham were allowed (138 resolved cases), compared with 37.3% across Art Unit 1600 over the last five years.
This examiner's interview lift is +36.1 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Richard Grant Peckham took 1,195 days on average from filing to allowance.
Richard Grant Peckham examines applications in Art Unit 1600 in Tech Center 1700 (Chemistry & Materials).
